Traws Capital Expenditures from 2010 to 2024

TRAW Stock   5.02  0.31  5.82%   
Traws Pharma Capital Expenditures yearly trend continues to be fairly stable with very little volatility. Capital Expenditures will likely drop to about 13.4 K in 2024. During the period from 2010 to 2024, Traws Pharma Capital Expenditures regression line of quarterly data had mean square error of 208.7 M and geometric mean of 0.00. View All Fundamentals
 
Capital Expenditures  
First Reported
2010-12-31
Previous Quarter
14 K
Current Value
13.4 K
Quarterly Volatility
23.1 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Traws Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Traws Pharma's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 15.6 K or Total Revenue of 193.2 K, as well as many indicators such as Price To Sales Ratio of 1.1 K, Dividend Yield of 0.0 or PTB Ratio of 30.16. Traws financial statements analysis is a perfect complement when working with Traws Pharma Valuation or Volatility modules.
  
Check out the analysis of Traws Pharma Correlation against competitors.
For more information on how to buy Traws Stock please use our How to Invest in Traws Pharma guide.

Latest Traws Pharma's Capital Expenditures Growth Pattern

Below is the plot of the Capital Expenditures of Traws Pharma over the last few years. Capital Expenditures are funds used by Traws Pharma to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Traws Pharma operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software. It is Traws Pharma's Capital Expenditures historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Traws Pharma's overall financial position and show how it may be relating to other accounts over time.
Capital Expenditures10 Years Trend
Slightly volatile
   Capital Expenditures   
       Timeline  

Traws Capital Expenditures Regression Statistics

Arithmetic Mean39,496
Geometric Mean0.00
Coefficient Of Variation58.42
Mean Deviation20,672
Median55,000
Standard Deviation23,072
Sample Variance532.3M
Range55K
R-Value(0.80)
Mean Square Error208.7M
R-Squared0.64
Significance0.0004
Slope(4,114)
Total Sum of Squares7.5B

Traws Capital Expenditures History

202413.4 K
202314 K
2021null
202015 K

About Traws Pharma Financial Statements

Traws Pharma investors use historical fundamental indicators, such as Traws Pharma's Capital Expenditures, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Traws Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Expenditures14 K13.4 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Traws Stock Analysis

When running Traws Pharma's price analysis, check to measure Traws Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Traws Pharma is operating at the current time. Most of Traws Pharma's value examination focuses on studying past and present price action to predict the probability of Traws Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Traws Pharma's price. Additionally, you may evaluate how the addition of Traws Pharma to your portfolios can decrease your overall portfolio volatility.